241 related articles for article (PubMed ID: 31974142)
41. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
42. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
[TBL] [Abstract][Full Text] [Related]
43. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Campbell J; Mohiuddin SM
Drugs Today (Barc); 2010 Oct; 46(10):757-64. PubMed ID: 21076712
[TBL] [Abstract][Full Text] [Related]
44. Optimal pharmacotherapy to combat the atherogenic lipid triad.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
[TBL] [Abstract][Full Text] [Related]
45. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Seber S; Ucak S; Basat O; Altuntas Y
Diabetes Res Clin Pract; 2006 Jan; 71(1):52-8. PubMed ID: 16009445
[TBL] [Abstract][Full Text] [Related]
46. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective.
Elam M; Lovato LC; Ginsberg H
Curr Opin Lipidol; 2011 Feb; 22(1):55-61. PubMed ID: 21102326
[TBL] [Abstract][Full Text] [Related]
47. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Muhlestein JB; May HT; Jensen JR; Horne BD; Lanman RB; Lavasani F; Wolfert RL; Pearson RR; Yannicelli HD; Anderson JL
J Am Coll Cardiol; 2006 Jul; 48(2):396-401. PubMed ID: 16843192
[TBL] [Abstract][Full Text] [Related]
48. Hyperlipidaemia and cardiovascular disease: do fibrates have a role?
Saha SA; Arora RR
Curr Opin Lipidol; 2011 Aug; 22(4):270-6. PubMed ID: 21519250
[TBL] [Abstract][Full Text] [Related]
49. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
Krysiak R; Gilowski W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507
[TBL] [Abstract][Full Text] [Related]
50. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Keating GM; Croom KF
Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
[TBL] [Abstract][Full Text] [Related]
51. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
Farnier M
Vasc Health Risk Manag; 2008; 4(5):991-1000. PubMed ID: 19183747
[TBL] [Abstract][Full Text] [Related]
52. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Steiner G
Cardiovasc Drugs Ther; 2009 Oct; 23(5):403-8. PubMed ID: 19757004
[TBL] [Abstract][Full Text] [Related]
53. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
Chan DC; Wong AT; Yamashita S; Watts GF
Atherosclerosis; 2012 Apr; 221(2):484-9. PubMed ID: 22341868
[TBL] [Abstract][Full Text] [Related]
54. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
Díaz Rodríguez Á
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
[TBL] [Abstract][Full Text] [Related]
55. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Papademetriou V; Lovato L; Tsioufis C; Cushman W; Applegate WB; Mottle A; Punthakee Z; Nylen E; Doumas M;
Am J Nephrol; 2017; 45(2):136-145. PubMed ID: 27992863
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
[TBL] [Abstract][Full Text] [Related]
57. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial.
Reyes-Soffer G; Ngai CI; Lovato L; Karmally W; Ramakrishnan R; Holleran S; Ginsberg HN
Diabetes Care; 2013 Feb; 36(2):422-8. PubMed ID: 23033246
[TBL] [Abstract][Full Text] [Related]
58. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
Ida S; Kaneko R; Murata K
Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163
[TBL] [Abstract][Full Text] [Related]
60. More clinical lessons from the FIELD study.
Fazio S
Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]